ZURICH & DÜSSELDORF, Germany--(BUSINESS WIRE)--Mar 4, 2013--EBD Group, the leading partnering firm for the global life science industry, will hold the fifth annual EuroMedtech™ partnering conference May 7–8 in Düsseldorf, Germany. The conference brings together leaders in medical technology, medtech decision makers and investors.

“The medical device industry continues to bring new technologies to market despite dealing with ongoing regulatory and reimbursement issues,” said Carola Schropp, President, EBD Group. “Forming strategic collaborations with large medical technology companies is an effective strategy for emerging innovator companies. EuroMedtech is the event dedicated to fostering these partnerships.” This year’s program features panels and workshops of interest to executives in the medtech life science sector, with topics ranging from point-of-care collaborations to telehealthcare.

One panel discussion will examine regulatory developments and unique features of each regulatory area that help or hinder plans to launch new products. The panel will be led by moderator Erik Vollebregt, Partner at Axon Partners.

“Navigating the regulatory landscape can be difficult for biotech companies, particularly at a time when regulations are changing and the need for high quality clinical data to support device submissions is increasing,” said Vicki Anastasi, Senior VP, Medical Devices, Aptiv Solutions, who is on the regulatory panel. “Aptiv Solutions helps clients understand the regulatory requirements for the development of both medicinal products and medical devices with a particular emphasis on innovative adaptive trial designs that bring efficiency and productivity benefits. I am very pleased to participate on this panel at EuroMedtech, as bringing medical device technologies to the market has never been more challenging.” The panel “From the trenches: Entrepreneur war stories” will be an important discussion of personal stories and strategies used by serial entrepreneurs. The panel will be led by Raman Minhas of ATPBio, who is also on the EuroMedtech Advisory Board.

“I have come across many fascinating ‘war stories’ from medtech entrepreneurs. Many of these lessons, along with insights as an investor, are topics I have written about in Medtech Value Investor blog,” said Minhas. “We’ll hear directly from entrepreneurs who have experience of start-ups, company building, and exits, along with the scars to prove it. This should be a fascinating discussion.” EuroMedtech is Europe’s leading medical technology partnering conference providing collaboration opportunities to medtech decision makers and investors. Participants meet with numerous potential partners and discuss in- and out-licensing, financing and other collaborative programs. EuroMedtech 2013 will again feature the popular Next Generation Presentation track for young entrepreneurial companies and the Company Presentation track for innovative medtech corporations.

EuroMedtech caters to companies involved in all parts of the advanced medical technology industry, from those serving mainline therapeutic categories such as drug delivery and augmented intervention in medicine, through diagnostics, imaging and eHealth to those involved in platform technologies such as micro and nanotechnological tools and implantable devices.

The deadline for presenting companies is March 8, 2013. Applications can be submitted online at

Register before March 8, 2013 to save EUR 200. Registration information for EuroMedtech can be found online at

In 2012, the conference hosted more than 300 delegates representing 205 companies from 22 countries who engaged in 755 one-to-one partnering meetings.

For more information, visit the EuroMedtech website: